| Mrs Christine Lorraine Doyle, ARNP, CPNP | |
|
1417 A Ave E, Suite 100, Oskaloosa, IA 52577-4202 | |
| (641) 673-7537 | |
| (641) 673-5235 |
| Full Name | Mrs Christine Lorraine Doyle |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Pediatrics |
| Location | 1417 A Ave E, Oskaloosa, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073592432 | NPI | - | NPPES |
| 3419721 | Medicaid | IA | |
| 03077 | Other | IA | WELLMARK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LP0200X | Nurse Practitioner - Pediatrics | C-068696 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Christine Lorraine Doyle, ARNP, CPNP 1417 A Ave E, Suite 100, Oskaloosa, IA 52577-4202 Ph: (641) 673-7537 | Mrs Christine Lorraine Doyle, ARNP, CPNP 1417 A Ave E, Suite 100, Oskaloosa, IA 52577-4202 Ph: (641) 673-7537 |
News Archive
Cardiologists have long grappled with how to best manage patients with coronary artery disease who report skin hypersensitivity to nickel or other metal components found in stents - small tubes placed in narrowed or weakened arteries to help improve blood flow to the heart. But new Mayo Clinic research, published in the April 16, 2012, issue of Circulation: Cardiovascular Interventions, may help allay these concerns.
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has been awarded two grants totaling $488,959 under the qualifying therapeutic discovery project ("QTDP") program established under Section 48D of the Internal Revenue Code. These grants were awarded based on applications CorMedix submitted for both its Neutrolin® and Deferiprone programs.
Doing exercise in hot environments leads to early fatigue owing to a range of physiological factors in which high body temperature is a significant one.
Fibrocell Science, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults.
› Verified 5 days ago
Stefanie Yearian, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3259 Fax: 641-672-3259 | |
Christine Beaird, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3100 | |
Mrs. Joyce Elaine Prough, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3159 | |
Tonya Johannes, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3360 | |
Danielle Rice, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 410 N 12th St, Oskaloosa, IA 52577 Phone: 641-672-3360 | |
Arthur Zacharjasz, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1229 C Ave E, Oskaloosa, Ia 52577, Oskaloosa, IA 52577 Phone: 641-672-3100 |